Evidence map›Paper›PMID 21856595›Full record

ArticleEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors.

Ajay Varanasi, Pavan Patel, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01722266. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01722266 phase3completed

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

Ran2012Enrolled72Registered outcomes7Posted comparisons0ConditionsType 1 DiabetesArmsliraglutide, Placebo
PMID 20404854PMID 20109994PMID 23807520PMID 17379054PMID 20019672PMID 17180352PMID 18996824PMID 19808924PMID 21646283PMID 20841306PMID 20207828other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Pathophysiology of Non Alcoholic Fatty Liver Disease.International journal of molecular sciences · 2016
    Review
  11. Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2016
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Incretin-based therapies: focus on effects beyond glycemic control alone.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2013
    Article
  18. Review
  19. Direct cardiovascular effects of glucagon like peptide-1.Diabetology & metabolic syndrome · 2013
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ajay VaranasiDivision of Endocrinology, Diabetes and Metabolism, State University of New York and Kaleida Health, Buffalo, New York 14209, USA.
Pavan Patel
Antoine Makdissi
Sandeep Dhindsa
Ajay Chaudhuri
Paresh Dandona

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess whether liraglutide, a glucagon-like peptide-1 receptor agonist, has cardioprotective properties in addition to its glycemic effects.

methodsWe performed a retrospective analysis of medical records of 110 obese patients with type 2 diabetes mellitus treated with liraglutide for at least 6 months between March 2010 and April 2011 at our tertiary care referral center. The variables analyzed were body mass index, hemoglobin A(1c) (A1C), systolic blood pressure (SBP), plasma C-reactive protein (CRP) concentrations, and serum lipids.

resultsIn our overall study cohort, we noted a reduction in mean weight from 120 ± 5 kg to 115 ± 3 kg and a decrease in mean A1C from 7.8% ± 0.6% to 7.2% ± 0.2%. The mean triglyceride concentration decreased from 173 ± 19 mg/dL to 151 ± 15 mg/dL, the mean SBP was reduced from 132 ± 6 mm Hg to 125 ± 4 mm Hg, and the mean CRP concentration declined from 4.7 ± 0.8 mg/L to 3.2 ± 0.4 mg/L after treatment with liraglutide for a minimal duration of 6 months and a mean duration of 7.5 months (for all the foregoing changes, P<.05). These variables decreased whether these patients were previously treated with orally administered hypoglycemic agents alone or in combination with insulin or exenatide.

conclusionOur findings in a clinical practice show that liraglutide is a potent antidiabetes drug, whether given in combination with orally administered agents or insulin or as a substitution for exenatide. It lowers body weight, A1C levels, SBP, and CRP and triglyceride concentrations.

Indexed as

Body Mass IndexCardiovascular DiseasesCohort StudiesC-Reactive ProteinDiabetes Mellitus, Type 2Drug Therapy, CombinationGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlycated HemoglobinHumansHyperglycemiaHypertensionHypertriglyceridemiaHypoglycemic AgentsInsulinLipidsC-Reactive ProteinGLP1R protein, humanGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinLipidsLiraglutideReceptors, Glucagon

Identifiers

PMID21856595

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.